Dystonia Panel
Use
The Dystonia Panel is designed for individuals with relevant clinical features or a suspected diagnosis of dystonia. It is particularly significant for individuals with symptom onset before age 20 years, those of Ashkenazi Jewish ancestry with early-onset generalized dystonia, and patients showing a sustained response to levodopa treatment.
Special Instructions
This test can be ordered via Exome or Genome platforms and includes options for Exome-Wide CNV Analysis and STAT testing, which incurs a 25% surcharge. Institutional pricing is available for logged-in users.
Limitations
The test's performance characteristics were validated by PreventionGenetics following CAP and CLIA regulations but have not been cleared or approved by the US Food and Drug Administration. The accuracy and completeness of test results directly correlate with the clinical information provided by the ordering physician.
New York Approved
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
14-21 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
Not provided
Minimum Volume
Not provided